Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of incretin treatment

Diabetes

Volumn 64, Issue 4, 2015, Pages 1395-1406

  Balestrieri, Maria Luisa ^a   Rizzo, Maria Rosaria ^a   Barbieri, Michelangela ^a   Paolisso, Pasquale ^a   D'Onofrio, Nunzia ^a   Giovane, Alfonso ^a   Siniscalchi, Mario ^b   Minicucci, Fabio ^b   Sardu, Celestino ^a   D'Andrea, Davide ^b   Mauro, Ciro ^b   Ferraraccio, Franca ^a   Servillo, Luigi ^a   Chirico, Fabio ^b   Caiazzo, Pasquale ^b   Paolisso, Giuseppe ^a   Marfella, Raffaele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; COLLAGEN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GELATINASE B; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCRETIN; LIRAGLUTIDE; SIRTUIN 6; TUMOR NECROSIS FACTOR ALPHA; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; SIRT6 PROTEIN, HUMAN; SIRTUIN;

AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; AGONISTS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; CAROTID ARTERIES; COLLAGEN; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; INCRETINS; INFLAMMATION; MALE; MIDDLE AGED; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, GLUCAGON; SIRTUINS;

EID: 84928984759     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1149     Document Type: Article

References (37)

1. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999;100: 1134-1146
2. Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003;108: 1527-1532
3. Michishita E, Park JY, Burneskis JM, Barrett JC, Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 2005;16: 4623-4635
4. Lappas M. Anti-inflammatory properties of sirtuin 6 in human umbilical vein endothelial cells. Mediators Inflamm 2012;2012: 597514
5. Kanfi Y, Peshti V, Gil R, et al. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010;9: 162-173
6. Grimley R, Polyakova O, Vamathevan J, et al. Over expression of wild type or a catalytically dead mutant of Sirtuin 6 does not influence NFkB responses. PLoS One 2012;7: E39847
7. Kim HS, Xiao C, Wang RH, et al. Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. Cell Metab 2010;12: 224-236
8. Michishita E, McCord RA, Berber E, et al. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature 2008;452: 492-496
9. Kawahara TLA, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009;136: 62-74
10. Favero G, Rezzani R, Rodella LF. Sirtuin 6 nuclear localization at cortical brain level of young diabetic mice: An immunohistochemical study. Acta Histochem 2014;116: 272-277
11. Vittone F, Liberman A, Vasic D, et al. Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. Diabetologia 2012;55: 2267-2275
12. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59: 1030-1037
13. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124: 2338-2349
14. Lee J, Hong SW, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One 2012;7: E31394
15. Makdissi A, Ghanim H, Vora M, et al. Sitagliptin exerts an antinflammatory action. J Clin Endocrinol Metab 2012;97: 3333-3341
16. Chaudhuri A, Ghanim H, Vora M, et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012;97: 198-207
17. Young B, Moore WS, Robertson JT, et al. An analysis of perioperative surgical mortality and morbility in the asymptomatic carotid atherosclerosis study. ACAS Investigators. Asymptomatic Carotid Atherosclerosis Study. Stroke 1996;27: 2216-2224
18. Moghissi ES, Korytkowski MT, DiNardo M, et al.; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009;32: 1119-1131
19. Marfella R, D'Amico M, Di Filippo C, et al. Increased activity of the ubiquitinproteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: Effects of rosiglitazone treatment. J Am Coll Cardiol 2006;47: 2444-2455
20. Balestrieri ML, Servillo L, Esposito A, et al. Poor glycaemic control in type 2 diabetes patients reduces endothelial progenitor cell number by influencing SIRT1 signalling via platelet-activating factor receptor activation. Diabetologia 2013;56: 162-172
21. Balestrieri ML, Giovane A, Milone L, Servillo L. Endothelial progenitor cells express PAF receptor and respond to PAF via Ca(2+)-dependent signaling. Biochim Biophys Acta 2010;1801: 1123-1132
22. Du F, Zhou J, Gong R, et al. Endothelial progenitor cells in atherosclerosis. Front Biosci (Landmark Ed) 2012;17: 2327-2349
23. Marfella R, D'Amico M, Esposito K, et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: Effects of rosiglitazone treatment. Diabetes 2006;55: 622-632
24. Etchegaray JP, Zhong L, Mostoslavsky R. The histone deacetylase SIRT6: At the crossroads between epigenetics, metabolism and disease. Curr Top Med Chem 2013;13: 2991-3000
25. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368: 1696-1705
26. Beauharnois JM, Bolívar BE, Welch JT. Sirtuin 6: A review of biological effects and potential therapeutic properties. Mol Biosyst 2013;9: 1789-1806
27. Sundaresan NR, Vasudevan P, Zhong L, et al. The sirtuin SIRT6 blocks IGFAkt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat Med 2012;18: 1643-1650
28. Spagnoli LG, Mauriello A, Sangiorgi G, et al. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004;292: 1845-1852
29. Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: Implications for the cardiovascular continuum in diabetes? Diabet Med 2013;30: 289-299
30. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012;59: 265-276
31. Barbieri M, Rizzo MR, Marfella R, et al. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 2013;227: 349-354
32. Erdogdu O, Eriksson L, Xu H, Sjöholm A, Zhang Q, Nyström T. Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. J Mol Endocrinol 2013;50: 229-241
33. Zeng Y, Li C, Guan M, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK-and MAPK-dependent mechanisms. Cardiovasc Diabetol 2014;13: 32-36
34. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: 1327-1335
35. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369: 1317-1326
36. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 938-953
37. Moreno PR, Murcia AM, Palacios IF, et al. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation 2000;102: 2180-2184